Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Biomaterials. 2019 Apr 12;209:79–87. doi: 10.1016/j.biomaterials.2019.04.020

Figure 4.

Figure 4.

(A) Primary human GBM cells GBM1A transfected with a single formulation of bioreducible R646 nanoparticles containing a mixture of five siRNA sequences showed simultaneous knockdown of all five targeted genes. (B) Cells transfected with 5x doses of each individual siRNA sequence showed reduced viability compared to control cells as did the siRNA mixture combination condition. (C) Reducing the functional siRNA dose while keeping the total siRNA amount the same by mixing in control scRNA results in an even more pronounced effect of the combination therapy. (D) Cells transfected with certain single siRNAs showed reduced migration capacity compared to control cells. Cells transfected with the mixture condition of all five siRNA sequences in combination showed optimal cell killing with a strong reduction in migration capacity. For B-D, a one-way ANOVA with post-hoc Dunnett’s test was used to determine statistically significant differences from the scRNA control (*p<0.05; **p<0.01) or the combination treatment (#p<0.05, ##p<0.01). A Bonferroni correction was used for the separate comparisons.